Amphastar Receives FDA Approval for Generic Iron Sucrose Injection to Treat Anemia in Chronic Kidney Disease Patients
Key Insights
Amphastar Pharmaceuticals received FDA approval for its generic iron sucrose injection (AMP-002) in three dosage strengths for treating iron deficiency anemia (search) in chronic kidney disease (search) patients.
The FDA determined that Amphastar's iron sucrose injection meets bioequivalence and therapeutic equivalence criteria to the reference drug Venofer®, which generated approximately $513 million in U.S. sales over the past 12 months.
The company plans to launch the generic iron sucrose injection in the third quarter of 2025, adding to its pipeline of complex generic and biosimilar products targeting markets worth over $9.5 billion combined.
Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the company's Abbreviated New Drug Application for Iron Sucrose Injection, USP in three dosage strengths: 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials. The generic iron replacement product, previously designated as AMP-002, is indicated for treating iron deficiency anemia (search) in patients with chronic kidney disease (search).
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer®, the reference listed drug. The approval represents a significant milestone for the Rancho Cucamonga-based biopharmaceutical company, which specializes in developing complex generic and proprietary injectable products.
Market Opportunity and Commercial Launch
The generic iron sucrose injection targets a substantial market opportunity. According to IQVIA data, U.S. sales for Venofer® totaled approximately $513 million for the 12 months ended June 30, 2025. Amphastar plans to launch its generic version in the third quarter of 2025.
"We are delighted to announce the FDA approval of our generic iron sucrose injection," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "This approval, once again, demonstrates our dedication to developing complex generics and leveraging cutting-edge, in-house manufacturing expertise to produce both active pharmaceutical ingredients and finished drug products under the highest regulatory standards in the U.S."
Expanding Pipeline Portfolio
The iron sucrose injection approval adds to Amphastar's robust development pipeline. The company currently has three abbreviated new drug applications and one biosimilar insulin candidate filed with the FDA, targeting products with a combined market size exceeding $2.5 billion. Additionally, Amphastar has three biosimilar products in development targeting markets worth more than $6 billion, and two generic products in development for markets exceeding $1 billion.
The market size data is based on IQVIA information for the 12 months ended June 30, 2025. Beyond generic products, the company is developing multiple proprietary products with injectable and intranasal dosage forms.
Company Focus and Manufacturing Capabilities
Amphastar focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. The company also sells insulin active pharmaceutical ingredient products. Most of Amphastar's finished products are used in hospital or urgent care clinical settings and are distributed through group purchasing organizations and drug wholesalers.
The FDA approval of iron sucrose injection reinforces Amphastar's manufacturing expertise in producing both active pharmaceutical ingredients and finished drug products under stringent U.S. regulatory standards. This capability positions the company to continue expanding its portfolio of complex generic medications that serve critical therapeutic needs in hospital and clinical settings.